These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23980685)

  • 21. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.
    de Groot JF; Fuller G; Kumar AJ; Piao Y; Eterovic K; Ji Y; Conrad CA
    Neuro Oncol; 2010 Mar; 12(3):233-42. PubMed ID: 20167811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BMP4 inhibits glioblastoma invasion by promoting E-cadherin and claudin expression.
    Zhao X; Sun Q; Dou C; Chen Q; Liu B
    Front Biosci (Landmark Ed); 2019 Mar; 24(6):1060-1070. PubMed ID: 30844730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BMP4 reverses multidrug resistance through modulation of BCL-2 and GDNF in glioblastoma.
    Liu B; Chen Q; Tian D; Wu L; Dong H; Wang J; Ji B; Zhu X; Cai Q; Wang L; Zhang S
    Brain Res; 2013 Apr; 1507():115-24. PubMed ID: 23466456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthetic chenodeoxycholic acid derivatives inhibit glioblastoma multiform tumor growth in vitro and in vivo.
    Yee SB; Yeo WJ; Park BS; Kim JY; Baek SJ; Kim YC; Seo SY; Lee SH; Kim JH; Suh H; Kim ND; Lim YJ; Yoo YH
    Int J Oncol; 2005 Sep; 27(3):653-9. PubMed ID: 16077913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
    Pichler J; Pachinger C; Pelz M; Kleiser R
    Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.
    Wang L; Liu Q; Zhao H; Cui K; Yao L; Nie F; Jin G; Hao A; Wong ST
    J Neurosci Res; 2013 Jan; 91(1):128-37. PubMed ID: 23115024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma.
    González-Gómez P; Crecente-Campo J; Zahonero C; de la Fuente M; Hernández-Laín A; Mira H; Sánchez-Gómez P; Garcia-Fuentes M
    Oncotarget; 2015 May; 6(13):10950-63. PubMed ID: 25860932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme.
    Lomax AJ; Hill PA; Ashley DM
    J Oncol Pharm Pract; 2013 Dec; 19(4):365-8. PubMed ID: 23235917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.
    Zhang W; Fulci G; Buhrman JS; Stemmer-Rachamimov AO; Chen JW; Wojtkiewicz GR; Weissleder R; Rabkin SD; Martuza RL
    Mol Ther; 2012 Jan; 20(1):37-45. PubMed ID: 21915104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-tissue factor (TF9-10H10) treatment reduces tumor cell invasiveness in a novel migratory glioma model.
    Harter PN; Dützmann S; Drott U; Zachskorn C; Hattingen E; Capper D; Gessler F; Senft C; Seifert V; Plate KH; Kögel D; Mittelbronn M
    Neuropathology; 2013 Oct; 33(5):515-25. PubMed ID: 23384223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
    Huynh H; Chow PK; Palanisamy N; Salto-Tellez M; Goh BC; Lee CK; Somani A; Lee HS; Kalpana R; Yu K; Tan PH; Wu J; Soong R; Lee MH; Hor H; Soo KC; Toh HC; Tan P
    J Hepatol; 2008 Jul; 49(1):52-60. PubMed ID: 18490075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluorescence-guided operation in recurrent glioblastoma multiforme treated with bevacizumab-fluorescence of the noncontrast enhancing tumor tissue?
    Wachter D; Kallenberg K; Wrede A; Schulz-Schaeffer W; Behm T; Rohde V
    J Neurol Surg A Cent Eur Neurosurg; 2012 Nov; 73(6):401-6. PubMed ID: 22777926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH; Shen YL; Keegan P; Pazdur R
    Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of VEGF blockade on the dynamics of the inflammatory landscape in glioblastoma-bearing mice.
    Soubéran A; Brustlein S; Gouarné C; Chasson L; Tchoghandjian A; Malissen M; Rougon G
    J Neuroinflammation; 2019 Oct; 16(1):191. PubMed ID: 31660979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
    Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.
    Piao Y; Liang J; Holmes L; Henry V; Sulman E; de Groot JF
    Clin Cancer Res; 2013 Aug; 19(16):4392-403. PubMed ID: 23804423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The homing and inhibiting effects of hNSCs-BMP4 on human glioma stem cells.
    Liu S; Yin F; Zhao M; Zhou C; Ren J; Huang Q; Zhao Z; Mitra R; Fan W; Fan M
    Oncotarget; 2016 Apr; 7(14):17920-31. PubMed ID: 26908439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.
    Salaun PY; Bodet-Milin C; Frampas E; Oudoux A; Saï-Maurel C; Faivre-Chauvet A; Barbet J; Paris F; Kraeber-Bodéré F
    Cancer; 2010 Feb; 116(4 Suppl):1053-8. PubMed ID: 20127950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.
    Guo J; Shinriki S; Su Y; Nakamura T; Hayashi M; Tsuda Y; Murakami Y; Tasaki M; Hide T; Takezaki T; Kuratsu J; Yamashita S; Ueda M; Li JD; Ando Y; Jono H
    Oncotarget; 2014 Aug; 5(15):6353-64. PubMed ID: 25071012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.